Published in Mol Ther on November 01, 2011
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther (2013) 1.04
HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther (2013) 0.86
Treatment of chemotherapy-refractory cancer in the advanced therapy access program. Mol Ther (2012) 0.86
Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol Ther (2014) 0.84
A potential therapeutic strategy for malignant mesothelioma with gene medicine. Biomed Res Int (2013) 0.79
Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med (2013) 0.79
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Mol Ther (2016) 0.77
T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. Mol Ther (2015) 0.76
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology (2015) 0.76
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol (2017) 0.75
Oncolytic virotherapy: the questions and the promise. Oncolytic Virother (2013) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 2.36
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res (2003) 2.33
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther (2010) 1.91
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Immunological features in patients with pneumonitis due to influenza A H1N1 infection. J Investig Allergol Clin Immunol (2011) 1.67
Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 1.62
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol (2001) 1.43
Clinical development directions in oncolytic viral therapy. Cancer Gene Ther (2011) 1.37
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm (2010) 1.36
Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology (2003) 1.35
Mitochondria: the calcium connection. Biochim Biophys Acta (2010) 1.35
Viral calciomics: interplays between Ca2+ and virus. Cell Calcium (2009) 1.33
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res (2010) 1.33
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer (2011) 1.26
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther (2010) 1.23
L-type calcium channels. Curr Pharm Des (2006) 1.16
Medications for migraine prophylaxis. Am Fam Physician (2006) 1.14
Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity. MBio (2010) 1.13
Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache (2009) 1.04
Oncolytic viruses from the perspective of the immune system. Future Microbiol (2009) 0.95
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Ann Med (2011) 0.89
Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord (2008) 0.88
Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs (1996) 0.85
Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J (2010) 0.84
E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther (2008) 0.83
Calcium channel blockers and modulation of innate immunity. Curr Opin Infect Dis (2011) 0.83
Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther (2010) 0.83
Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells. Clin Exp Immunol (2009) 0.77
Studies on verapamil in the treatment of essential hypertension: a review. Br J Clin Pharmacol (1986) 0.77
Welcome--the calcium channel blockers. Chest (1981) 0.77
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Harmful impact of EU clinical trials directive. BMJ (2006) 4.85
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 3.22
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer (2013) 2.24
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther (2010) 1.91
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet (2010) 1.78
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol (2009) 1.70
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther (2007) 1.68
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat Biotechnol (2003) 1.58
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther (2012) 1.57
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology (2005) 1.56
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer (2006) 1.53
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm (2010) 1.36
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res (2010) 1.33
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res (2012) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res (2012) 1.28
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer (2011) 1.26
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther (2012) 1.18